Sign in

You're signed outSign in or to get full access.

Rodney Reeves

Research Analyst at Leerink Partners

Rodney Reeves is an analyst at Leerink Partners, specializing in healthcare sector research with a focus on biopharma and healthcare services. He has participated in earnings calls and covered companies like ARS Pharmaceuticals Inc., demonstrating sector expertise though publicly available performance track record and rankings are currently limited. Reeves' specific career timeline, including the year he joined Leerink Partners and any prior positions, is not clearly documented in public sources. Details regarding his professional credentials and securities licenses are also unavailable at this time.

Rodney Reeves's questions to ARS Pharmaceuticals (SPRY) leadership

Question · Q2 2025

Representing Rodney Reeves of Leerink Partners, an analyst asked about the potential ceiling for commercial coverage without prior authorization, particularly concerning CVS Caremark, and the potential revenue impact of achieving full coverage without PAs.

Answer

Co-Founder, President, and CEO Richard Lowenthal stated that the company has not seen signs of a ceiling for coverage. He explained that while a majority of CVS Caremark members still require a prior authorization, these are being approved over 80% of the time. As other payers grant open access, it frees up physician capacity to manage the remaining PAs, ensuring steady access.

Ask follow-up questions

Fintool

Fintool can predict ARS Pharmaceuticals logo SPRY's earnings beat/miss a week before the call